United Therapeutics $UTHR CEO Martine Rothblatt won’t be looking over her shoulders as a potential rival to United’s lead drug makes its way through an FDA review, battling over her patents. She bought it instead.
United this morning handed out a nice premium to acquire little SteadyMed $STDY, paying $4.46 for a stock that closed Friday at $2.65 with a market cap of $70 million. United will also hand over another $2.63 a share based on their progress in scoring an approval for SteadyMed’s drug/device combo for pulmonary arterial hypertension, which uses a reformulation of United’s Remodulin. The total value of the deal — including the contingency payment — stretches up to $216 million.
That’s a bargain.
SteadyMed has been patiently working through a stinging refuse-to-file rejection from the FDA last summer, setting back plans to launch Trevyent. But they endured. The company sat down with regulators and worked out a plan to satisfy some additional data demands, looking to field a “repeat of in vitro Design Verification testing on the final to-be-marketed Trevyent product, supported by pharmacokinetic modelling and Process Validation.”
At the same time, little SteadyMed has been fighting a successful battle to invalidate United’s crucial ‘393 patent for the active ingredient in Remodulin, Tyvaso and Orenitram. The buyout would presumably put an end to that fight. Remodulin made $670 million last year, more than a third of its $1.7 billion in revenue. Treprostinil accounts for the lion’s share of its cash flow.
SteadyMed outlined plans for a comeback application later this year, but its stock remained in the basement, allowing United to scoop it up cheap.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.Free Subscription